NanoViricides Secures $2 Million in Registered Direct Offering for NV-387 Development

NanoViricides (NYSE-A: NNVC) has announced a registered direct offering to raise approximately $2 million in gross proceeds from a single institutional investor. Under the agreement, the company will sell slightly over 1.3 million common shares or pre-funded warrants, accompanied by warrants to purchase an equal number of shares at an exercise price of $1.75, expiring in three years. This financing aims to support the company's near-term focus on a Phase II clinical trial for its lead drug candidate, NV-387, targeting monkeypox treatment in the Democratic Republic of Congo, which has received regulatory approval from ACOREP. Additionally, the US FDA recently granted orphan drug designation to NV-387 for measles treatment, with further applications pending for MPox and smallpox indications. As of March 31, 2026, NanoViricides reported cash reserves of $3.38 million. The company also maintains access to an at-the-market stock facility and an undrawn $3 million credit line from its founder, providing additional financial flexibility as it advances its clinical pipeline and regulatory strategies for rare pediatric diseases.